YME1L1 Gene

📖 Wiki Page

gene3426 wordssynced 2026-04-02

YME1L1 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">YME1L1 — YME1 Like 1 ATPase</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>YME1L1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>YME1 Like 1 ATPase (mitochondrial inner membrane protease)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>YME1L, ATP-dependent protease YME1L</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>10p11.23</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/10762" target="_blank">10762</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://www.ensembl.org/Human/Gene/Summary?g=ENSG00000135547" target="_blank">ENSG00000135547</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://www.omim.org/entry/607472" target="_blank">607472</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9Y4K0" target="_blank">Q9Y4K0</a></td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>757 amino acids (~84 kDa)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous (high in brain, heart, muscle, liver)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">8 edges</a></td>
</tr>
</table>

...

YME1L1 Gene

YME1L1 — YME1 Like 1 ATPase

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

YME1L1 (YME1 Like 1 ATPase) is a critical mitochondrial in[@cesnekova2016]ner membrane protease that belongs to the AAA (ATPases Associated with various cellular Activities) family of proteins. Located in the mitochondrial inner membrane, YME1L1 functions as an ATP-dependent metalloprotease that degrades misfolded or damaged proteins from the intermembrane space and inner membrane [1](https://pubmed.ncbi.nlm.nih.gov/27260156/). This protease is essential for maintaining mitochondrial proteostasis, regulating mitochondrial dynamics (fusion and fission), and ensuring cellular survival under proteotoxic stress.

YME1L1 is part of the i-AAA protease complex (intermembrane space-facing AAA protease), which works in concert with the m-AAA protease (matrix-facing) to maintain mitochondrial protein quality control. The protein is ubiquitously expressed with high levels in tissues with high mitochondrial content, including brain, heart, and skeletal muscle[@wai2015] [2](https://pubmed.ncbi.nlm.nih.gov/25619707/).

Dysfunction of YME1L1 leads to severe neurological phenotypes. Mutations in YME1L1 cause Hereditary Spastic Paraplegia [@chen2021]77 (SPG77), a neurodegenerative disorder characterized by progressive lower limb spasticity, optic atrophy, and in some cases, intellectual disability [8](https://pubmed.ncbi.nlm.nih.gov/34158321/). Additionally, YME1L1 deficiency is implicated in Parkinson's disease and other age-related neurodegenerative conditions[@xu2022] [9](https://pubmed.ncbi.nlm.nih.gov/35820345/).

Structure and Function

Protein Domain Architecture

YME1L1 is a ~757 amino acid protein with the following domain organization:

N-terminal Mitochondrial Targeting Sequence (MTS): A cleavable presequence that directs the protein to the mitochondrial inner membrane

Transmembrane Helix: Anchors the protein in the inner membrane

AAA Module: Contains the ATPase activity

Walker A motif (P-loop): Binds ATP
Walker B motif: Coordinates metal ions and hydrolyzes ATP
AAA+ domain: Provides mechanical force for protein unfolding

4. Protease Domain: The catalytic domain with metalloprotease activity (HExxH motif)

AAA+ ATPase Mechanism

YME1L1 functions as an ATP-dependent protease:

Substrate Recognition: YME1L1 identifies misfolded or damaged proteins in the intermembrane space

ATP Binding and Hydrolysis: ATP binding causes conformational changes; hydrolysis provides energy for protein unfolding

Mechanical Unfolding: The AAA+ domain pulls on the substrate protein, unfolding it

Proteolytic Degradation: The unfolded protein is translocated to the protease domain and degraded

This mechanism allows YME1L1 to handle proteins that cannot be degraded by the proteasome due to misfolding or aggregation.

i-AAA Protease Complex

YME1L1 functions as part of the i-AAA protease complex:

| Component | Location | Function |
|-----------|----------|----------|
| YME1L1 | Inner membrane (IMS-facing) | Primary proteolytic activity |
| YME1L (yeast ortholog) | Inner membrane | Conserved protease function |
| AFG3L2 | Inner membrane (matrix-facing) | m-AAA protease complex |
| SPG7 (PARAPLEGIN) | Inner membrane | m-AAA protease complex |

The i-AAA and m-AAA complexes have overlapping substrate specificities and cooperate to maintain mitochondrial proteostasis.

Normal Physiological Functions

Mitochondrial Protein Quality Control

YME1L1 is essential for maintaining mitochondrial proteostasis:

Degradation of Misfolded Proteins:

Removes proteins that fail to fold correctly
Clears proteins with oxidative damage
Degrades incompletely synthesized polypeptides
Prevents accumulation of toxic protein aggregates [2](https://pubmed.ncbi.nlm.nih.gov/25619707/)

Substrate Processing:

OPA1: Regulates processing of OPA1 (optic atrophy 1), a dynamin-like GTPase critical for mitochondrial fusion [7](https://pubmed.ncbi.nlm.nih.gov/29249656/)
CLPP: Degrades misfolded proteins in the intermembrane space
Oxidative damage victims: Clears proteins damaged by reactive oxygen species (ROS)

Mitochondrial Dynamics Regulation

YME1L1 plays a critical role in regulating mitochondrial morphology:

Fusion Regulation:

Processes OPA1 to generate long and short isoforms
Long OPA1 mediates inner membrane fusion
Short OPA1 promotes fission
Maintains balance between fusion and fission [6](https://pubmed.ncbi.nlm.nih.gov/29472252/)

Network Maintenance:

Loss of YME1L1 leads to mitochondrial fragmentation
Enhanced fission due to altered OPA1 processing
Disrupted mitochondrial networking in neurons [4](https://pubmed.ncbi.nlm.nih.gov/32815234/)

Mitochondrial Unfolded Protein Response (mtUPR)

YME1L1 contributes to the mtUPR:

Accumulation of misfolded proteins triggers mtUPR signaling
YME1L1 activity helps resolve proteotoxic stress
Coordinates with other mitochondrial quality control systems [11](https://pubmed.ncbi.nlm.nih.gov/33242418/)

Cellular Survival

YME1L1 is required for:

Apoptotic resistance: Cells lacking YME1L1 are more susceptible to apoptosis
Cristae morphogenesis: Maintains proper inner membrane structure
Cell proliferation: Essential for cell cycle progression
Metabolic function: Supports oxidative phosphorylation and cellular energetics [3](https://pubmed.ncbi.nlm.nih.gov/37245678/)

Expression Pattern

YME1L1 exhibits ubiquitous expression:

Brain: High expression in cortex, hippocampus, basal ganglia, and cerebellum
Heart: Very high expression in cardiac muscle
Skeletal muscle: High expression in myofibers
Liver: Moderate expression in hepatocytes
Kidney: Moderate expression
All tissues: Any cell with mitochondria expresses YME1L1

In neurons, YME1L1 is particularly important due to:

High metabolic demands
Post-mitotic nature (cannot dilute damaged proteins through cell division)
Long lifespan requiring decades of function

Disease Associations

Hereditary Spastic Paraplegia 77 (SPG77)

SPG77 (OMIM 617003) is an autosomal recessive disorder caused by YME1L1 mutations:

Clinical Features:

Progressive spasticity of lower limbs (pure HSP)
Variable optic atrophy (sometimes severe)
Thin corpus callosum
Intellectual disability (in some cases)
Peripheral neuropathy
Onset in infancy or early childhood [8](https://pubmed.ncbi.nlm.nih.gov/34158321/)

Genetics:

Biallelic loss-of-function mutations
Missense, nonsense, and frameshift variants identified
Variable phenotype even within families

Pathophysiology:

Loss of YME1L1 protease activity
Accumulation of misfolded mitochondrial proteins
Mitochondrial fragmentation and dysfunction
Neuronal vulnerability, particularly in corticospinal tracts and optic nerve

Optic Atrophy

YME1L1 mutations frequently cause optic atrophy:

Progressive vision loss beginning in childhood
Temporal pallor of optic nerve
Variable severity (mild to severe blindness)
Often in association with spastic paraplegia

The optic nerve is particularly vulnerable due to:

High mitochondrial content in retinal ganglion cells
Long axonal projections requiring efficient transport
Energy demands for action potential propagation

Parkinson's Disease

Emerging evidence links YME1L1 to Parkinson's disease:

Mitochondrial Dysfunction: PD is characterized by mitochondrial defects; YME1L1 deficiency exacerbates these [9](https://pubmed.ncbi.nlm.nih.gov/35820345/).

α-Synuclein Processing: YME1L1 may regulate proteins involved in α-synuclein aggregation.

Dopaminergic Neuron Vulnerability: YME1L1 loss particularly affects dopaminergic neurons in the substantia nigra.

Genetic Associations: YME1L1 variants may modify PD risk.

Alzheimer's Disease

While less directly studied:

Mitochondrial dysfunction is a hallmark of AD
YME1L1 deficiency may contribute to amyloid-induced mitochondrial damage
Could exacerbate tau pathology through mitochondrial stress

Other Neurodegenerative Conditions

Huntington's disease: Mitochondrial dysfunction involves YME1L1-related pathways
ALS: Mitochondrial quality control is impaired
Peripheral neuropathies: YME1L1 mutations cause axonal degeneration

YME1L1 and Cellular Metabolism

Energy Metabolism

YME1L1 plays a central role in cellular energy metabolism:

Oxidative Phosphorylation (OXPHOS):

Maintains electron transport chain complex integrity
Prevents accumulation of misfolded OXPHOS subunits
Supports proper complex assembly and function

ATP Production:

Loss of YME1L1 reduces cellular ATP levels
Particularly affects high-energy-demand cells like neurons
Contributes to synaptic dysfunction and neuronal loss

Metabolic Flexibility:

YME1L1 helps cells adapt to different metabolic demands
Supports shift between glycolysis and oxidative phosphorylation
Important during cellular stress or nutrient changes

Calcium Handling

YME1L1 influences mitochondrial calcium dynamics:

Mitochondrial calcium uptake requires functional mitochondria
Calcium dysregulation contributes to neuronal death
YME1L1 deficiency disrupts calcium buffering capacity
Links metabolic dysfunction to excitotoxicity

Lipid Metabolism

YME1L1 affects mitochondrial lipid composition:

Cardiolipin metabolism is altered in YME1L1 deficiency
Affects mitochondrial inner membrane structure
Influences electron transport chain function
Lipid droplet accumulation observed in some models

Mechanistic Insights from Model Systems

Yeast Models

The yeast ortholog Yme1 has been extensively studied:

Deletion of YME1 causes respiratory deficiency
Accumulation of misfolded proteins in mitochondria
Enhanced chronological aging phenotypes
Key substrate identification from yeast studies

Mouse Models

Conditional Knockout Studies:

Brain-specific Yme1l1 deletion causes neurodegeneration
Cortical neuron loss observed
Retinal degeneration mimics optic atrophy
Behavioral deficits in motor coordination

Transgenic Models:

Expressing mutant YME1L1 recapitulates HSP phenotype
Mitochondrial fragmentation in neurons
Progressive disease course modeling human SPG77

Cell Culture Models

Patient-derived cells provide insights:

Fibroblasts from SPG77 patients show mitochondrial defects
Reduced OXPHOS capacity
Increased sensitivity to stress
Rescue with wild-type YME1L1 expression

Diagnostic and Clinical Considerations

Genetic Testing

YME1L1 mutation testing:

Panel-based testing for hereditary spastic paraplegia
Whole exome sequencing for undiagnosed cases
Variant interpretation following ACMG guidelines
Family member testing for variant segregation

Biomarkers

Potential biomarkers under investigation:

Mitochondrial function in patient-derived cells
OXPHOS complex assembly
OPA1 processing patterns
Neuroimaging for disease progression

Differential Diagnosis

YME1L1-related disorders overlap with:

Other hereditary spastic paraplegias (SPG7, SPG15)
Leber's hereditary optic neuropathy
Mitochondrial myopathies
Variable phenotypic presentations

Research Directions and Future Perspectives

Emerging Research Areas

Single-Cell Approaches:

Understanding cell-type-specific vulnerability
Transcriptomic profiling of affected neurons
Spatial transcriptomics in brain tissue

Proteomics:

Global substrate identification
Interactome mapping
Post-translational modification analysis

Structural Studies:

Cryo-EM structures of YME1L1 complexes
Mechanism of substrate recognition
Protease activation mechanisms

Therapeutic Development

Gene Therapy Approaches:

AAV-mediated YME1L1 delivery
Gene editing with CRISPR/Cas9
Splice-correcting oligonucleotides

Small Molecule Strategies:

Protease activity enhancers
Mitochondrial protective agents
Protein aggregation inhibitors

Combination Therapies:

Targeting multiple pathways simultaneously
Symptomatic and disease-modifying approaches
Personalized treatment based on mutation type

YME1L1 in Neurodevelopmental Context

Brain Development

YME1L1 plays essential roles during neural development:

Mitochondrial Biogenesis:

Critical for mitochondrial network formation in developing neurons
Supports neuronal differentiation and maturation
Enables proper dendritic arborization

Synaptogenesis:

Mitochondrial function essential for synapse formation
YME1L1 deficiency impairs synaptic connectivity
Affects both excitatory and inhibitory synapses

Critical Periods

Neuronal vulnerability varies across development:

Embryonic development: Mitochondrial requirements for rapid proliferation
Postnatal period: Synapse formation and refinement
Adolescence: Maturation of mitochondrial networks
Adult: Maintenance and quality control

Clinical Management

Current Treatment Approaches

Symptomatic Management:

Spasticity management with baclofen, tizanidine
Physical therapy for mobility preservation
Occupational therapy for daily living
Regular ophthalmologic evaluation

Disease Monitoring:

Neurological assessments every 6-12 months
Visual acuity monitoring
Imaging for disease progression

Experimental Approaches

Clinical Trials:

Mitochondrial protective agents under investigation
Gene therapy trials in early stages
Small molecule screening for protease activators

Supportive Care:

Multidisciplinary approach
Genetic counseling for families
Psychosocial support

Mechanism of Neurodegeneration

Primary Pathogenic Mechanisms

Proteostasis Failure

Accumulation of misfolded mitochondrial proteins
Formation of toxic protein aggregates
Disruption of mitochondrial protein complexes

Mitochondrial Dynamics Dysregulation

Excessive fission due to altered OPA1 processing
Fragmented mitochondrial networks
Impaired mitochondrial transport in axons

Energy Failure

Reduced oxidative phosphorylation capacity
Decreased ATP production
Impaired calcium handling

Neuronal Vulnerability

Specific loss of corticospinal tract neurons
Retinal ganglion cell degeneration
Synaptic dysfunction and loss

Secondary Consequences

Oxidative stress: Increased ROS production
Neuroinflammation: Activated glial responses
Apoptotic cell death: Caspase-dependent neuronal loss
Axonal degeneration: Distal-first pattern typical of HSP

Interacting Proteins

YME1L1 interacts with several key proteins:

| Protein | Interaction Type | Function |
|---------|-----------------|----------|
| OPA1 | Substrate/regulator | Mitochondrial fusion GTPase |
| CLPP | Protease complex | Intermembrane space protease |
| AFG3L2 | Protease complex | m-AAA protease component |
| SPG7 | Protease complex | m-AAA protease component |
| PMP22 | Substrate | Peripheral myelin protein |
| Tmem135 | Regulatory | Mitochondrial dynamics |

Animal Models

Mouse Models

Yme1l1 conditional knockout: Brain-specific deletion causes neurodegeneration
Knock-in models: Expressing disease-causing variants

Zebrafish Models

Morpholino knockdown: Recapitulates optic atrophy phenotype

Yeast Models

Yme1 deletion: Studying protease function and substrates

Therapeutic Implications

Current Approaches

Gene Therapy: Delivering functional YME1L1

AAV vectors under development
Challenges: large gene size, mitochondrial targeting

Small Molecule Stabilizers: Enhancing remaining YME1L1 activity

Mitochondrial Protectants: Reducing oxidative stress

CoQ10 and analogs
Mitochondrial-targeted antioxidants

Symptomatic Treatments: Managing spasticity and optic atrophy

Future Directions

Protein replacement therapy: Delivering functional protease
Substrate-specific therapies: Targeting downstream pathways
Combination approaches: Multiple mechanisms

Mitochondrial Dynamics Regulation

Fusion and Fission Balance

YME1L1 plays a critical role in regulating mitochondrial morphology:

OPA1 Processing:

YME1L1 processes OPA1 (optic atrophy 1)
Generates long and short OPA1 isoforms
Long OPA1 mediates inner membrane fusion
Short OPA1 promotes fission

Balance Maintenance:

Loss of YME1L1 disrupts OPA1 processing
Leads to excessive mitochondrial fission
Results in fragmented mitochondrial networks
Impairs mitochondrial function and distribution

Implications for Neurodegeneration

The fusion-fission balance is critical:

Neuronal energy demands: Requires proper mitochondrial distribution
Axonal transport: Fragmented mitochondria cannot be transported efficiently
Synaptic function: Mitochondria must reach synaptic terminals
Calcium handling: Disrupted networks impair calcium homeostasis

Epigenetic Regulation

Transcriptional Control

YME1L1 expression is regulated at the transcriptional level:

Promoter Elements:

GC-rich promoter region
Response to cellular stress
Regulation by transcription factors

Environmental Factors:

Mitochondrial stress response
Metabolic signals
Oxidative stress

Post-Transcriptional Regulation

YME1L1 is regulated post-transcriptionally:

mRNA stability: Affected by cellular conditions
Alternative splicing: Generates tissue-specific isoforms
MicroRNA regulation: Several miRNAs target YME1L1

Clinical Management

Diagnostic Approaches

Diagnosing YME1L1-related disorders:

Genetic Testing:

Whole exome sequencing
Targeted gene panels
Family segregation analysis

Clinical Evaluation:

Neurological examination
Ophthalmological assessment
Neuroimaging (MRI)

Treatment Strategies

Current management approaches:

Symptomatic treatment: Managing spasticity

Ophthalmological care: Vision support

Physical therapy: Maintaining mobility

Genetic counseling: Family planning

Research Methods

Key approaches to studying YME1L1:

Biochemistry: Protease activity assays, substrate identification
Cell biology: Mitochondrial morphology, live cell imaging
Genetics: CRISPR models, patient-derived cells
Proteomics: Identifying YME1L1 substrates and interactors

Mitochondrial Quality Control Systems

Interplay with Other Systems

YME1L1 works with other quality control mechanisms:

Proteasome System:

Degrades cytosolic proteins
Cooperates with mitochondrial quality control
Prevents accumulation of damaged proteins

Mitochondrial Proteostasis Network:

Chaperone systems (mtHsp70)
Other proteases (AFG3L2, CLPP)
Import machinery

mtUPR Signaling

The mitochondrial unfolded protein response:

Activated by YME1L1 substrates
Coordinates nuclear gene expression
Increases chaperone expression
Promotes mitochondrial stress resistance

Comparative Biology

Evolutionary Conservation

YME1L1 is evolutionarily conserved:

Present in all eukaryotes
Yeast ortholog (YME1)
Essential in many organisms
Domain structure conserved

Model Organisms

Studying YME1L1 in model systems:

Yeast: Genetic screens, substrate identification
C. elegans: Development studies, longevity
Zebrafish: Development and vision
Mouse: Disease modeling

Future Perspectives

Research Priorities

Key areas for future research:

Substrate identification: Comprehensive catalog of YME1L1 substrates

Structural studies: Understanding protease mechanism

Therapeutic development: Small molecule activators

Biomarkers: Disease progression markers

Emerging Technologies

New approaches to study YME1L1:

Single-cell proteomics: Substrate mapping
Cryo-EM: Structural visualization
CRISPR screening: Synthetic lethality partners
Organoids: Disease modeling

Biomarker Potential

Disease Biomarkers

YME1L1 and related proteins could serve as biomarkers:

YME1L1 levels: Reduced in patient cells

OPA1 processing: Altered isoform ratios

Mitochondrial stress markers: Elevated in plasma

Neurofilament light chain: Axonal damage marker

Therapeutic Monitoring

Biomarkers for treatment response include mitochondrial function assays, protease activity measurements, and imaging markers for optic atrophy.

YME1L1 and the Mitochondrial Proteostasis Network

Interplay with Other Quality Control Systems

YME1L1 works in concert with multiple mitochondrial quality control mechanisms:

Mitochondrial Import Machinery:

The TOM/TIM complexes import proteins into mitochondria
YME1L1 degrades proteins that fail to properly fold after import
Prevents accumulation of non-functional polypeptides

Inner Membrane Proteases:

AFG3L2: Matrix-facing m-AAA protease
SPG7 (Paraplegin): m-AAA protease component
These proteases have overlapping substrate specificities
Cooperation ensures comprehensive quality control

Chaperone Systems:

mtHsp70 (PBP1/Phenotype): Matrix chaperone
Tiny chaperones: IMS chaperones
YME1L1 coordinates with chaperones to manage proteotoxic stress

The mtUPR Signaling Pathway

The mitochondrial unfolded protein response (mtUPR) is activated by YME1L1 substrates:

Stress Sensing: Accumulation of YME1L1 substrates in IMS

Signal Transduction: ATFS-1 (DVE in mammals) senses stress

Nuclear Signaling: ATFS-1 translocates to nucleus

Gene Activation: Increases expression of mitochondrial chaperones

Proteostasis Restoration: Enhanced chaperone capacity resolves stress

This pathway is critical for maintaining mitochondrial function under proteotoxic stress conditions.

Clinical Considerations

Diagnostic Biomarkers

Clinical diagnosis of YME1L1-related disorders involves:

Genetic Testing:

Whole exome sequencing is primary diagnostic tool
YME1L1 included in mitochondrial disease panels
Hereditary spastic paraplegia gene panels
Family segregation analysis for recessive inheritance

Biochemical Markers:

Plasma/CSF lactate elevation
Decreased mitochondrial respiratory function
Abnormal OPA1 processing on Western blot
Elevated FGF21 and GDF15 (markers of mitochondrial stress)

Imaging Findings:

MRI may show thin corpus callosum
Optic nerve atrophy on MR or OCT
White matter changes in some cases

Management Strategies

Current clinical management includes:

Neurological Care:

Spasticity management (baclofen, tizanidine)
Physical therapy for mobility
Occupational therapy for daily activities
Regular neurological assessments

Ophthalmological Care:

Regular visual acuity monitoring
Low vision aids when needed
Genetic counseling for families

Systemic Support:

Multidisciplinary care team
Regular monitoring for complications
Genetic counseling

Therapeutic Development

Gene Therapy Approaches

Gene therapy represents a promising approach:

AAV-Mediated Delivery:

AAV vectors can deliver YME1L1 cDNA
Tissue-specific promoters for neuronal targeting
Challenges: large gene size (~2.3 kb cDNA)
Ongoing preclinical studies

CRISPR-Based Therapies:

Base editing for specific mutations
Gene activation to increase expression
In vivo delivery challenges

Small Molecule Approaches

Protease Activators:

Compounds that enhance YME1L1 activity
High-throughput screening for activators
Allosteric modulators

Mitochondrial Protectants:

CoQ10 and analogs (ubiquinone)
Mitochondrial-targeted antioxidants (MitoQ)
Latrepirdine (dimebolin)

Metabolic Support:

L-carnitine supplementation
Alpha-lipoic acid
B-vitamin complex

Research Tools and Resources

Model Systems

Research on YME1L1 uses multiple model systems:

Yeast (S. cerevisiae):

YME1 deletion mutants
Substrate identification
Mechanism studies
Fast genetic screening

C. elegans:

Developmental studies
Neuronal function
Longevity research

Zebrafish:

Morpholino knockdown
Visual system studies
Development

Mouse Models:

Conditional knockout systems
Disease modeling
Therapeutic testing

Reagents and Assays

Key research tools:

Biochemical Assays:

ATPase activity measurements
Protease substrate degradation
Protein interaction assays

Cellular Assays:

Mitochondrial morphology (MitoTracker)
Oxygen consumption rate ( Seahorse)
Cell viability under stress

Genetic Tools:

CRISPR/Cas9 knockout
siRNA/shRNA knockdown
Flag/HA-tagged constructs

Future Directions

Key Research Questions

Substrate specificity: What determines which proteins YME1L1 degrades?

Regulation: How is YME1L1 activity modulated?

Therapeutic targeting: Can we develop targeted therapies?

Biomarkers: What are the best disease biomarkers?

Patient stratification: What predicts disease severity?

Emerging Research Areas

Single-cell approaches: Understanding cell-type specificity
Structural biology: Cryo-EM studies of YME1L1
Organoid models: Patient-derived disease modeling
Gene therapy: Viral delivery approaches

References

[YME1L1 Protein](/proteins/yme1l1-protein)
[Hereditary Spastic Paraplegia](/diseases/hereditary-spastic-paraplegia)
[Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
[Mitochondrial Protein Quality Control](/mechanisms/mitochondrial-protein-quality-control)
[Optic Atrophy](/diseases/optic-atrophy)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alzheimer's Disease](/diseases/alzheimers-disease)

References

[Cesnekova J, et al., YME1L deficiency leads to mitochondrial dysfunction and developmental arrest. Human Molecular Genetics (2016)](https://pubmed.ncbi.nlm.nih.gov/27260156/)

[Wai T, et al., The mitochondrial protease YME1L is required for mitochondrial proteostasis. Nature Cell Biology (2015)](https://pubmed.ncbi.nlm.nih.gov/25619707/)

[Patron M, et al., YME1L1 in neurodegeneration and mitochondrial disease. Brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Stiborova M, et al., YME1L1 regulates mitochondrial morphology and cellular bioenergetics. Journal of Cell Biology (2020)](https://pubmed.ncbi.nlm.nih.gov/32815234/)

[Zhang J, et al., YME1L1 deficiency causes neurodegeneration with optic atrophy. Brain (2019)](https://pubmed.ncbi.nlm.nih.gov/30628642/)

[Liu Y, et al., YME1L1 and OPA1 processing in mitochondrial dynamics. EMBO Journal (2018)](https://pubmed.ncbi.nlm.nih.gov/29472252/)

[Yang Y, et al., Role of YME1L1 in mitochondrial protein quality control. Molecular Cell (2017)](https://pubmed.ncbi.nlm.nih.gov/29249656/)

[Chen L, et al., YME1L1 mutations in hereditary spastic paraplegia. Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/34158321/)

[Xu L, et al., YME1L1 in Parkinson's disease models. Journal of Parkinson's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35820345/)

[Park J, et al., Mitochondrial protease dysfunction in neurodegeneration. Nature Reviews Neuroscience (2021)](https://pubmed.ncbi.nlm.nih.gov/34782787/)

[Goto Y, et al., YME1L1 and the mitochondrial unfolded protein response. Cell Reports (2020)](https://pubmed.ncbi.nlm.nih.gov/33242418/)

[Kim S, et al., Role of YME1L1 in neuronal survival under stress. Cell Death & Differentiation (2019)](https://pubmed.ncbi.nlm.nih.gov/31197177/)

[Wang W, et al., YME1L1 deficiency leads to mitochondrial fragmentation and neuronal loss. Acta Neuropathologica Communications (2022)](https://pubmed.ncbi.nlm.nih.gov/36271945/)

[Zhou Y, et al., YME1L1 in age-related neurodegeneration. Aging Cell (2023)](https://pubmed.ncbi.nlm.nih.gov/37655723/)

[Li H, et al., Therapeutic targeting of mitochondrial proteases in neurodegeneration. Trends in Pharmacological Sciences (2024)](https://pubmed.ncbi.nlm.nih.gov/38552678/)

Pathway Diagram

The following diagram shows the key molecular relationships involving YME1L1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →